rs28937590
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 13P and 1B. PM2PM5PP3PP5_Very_StrongBP4
The ENST00000359273.8(BCS1L):c.232A>G(p.Ser78Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000269 in 1,614,168 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S78I) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000359273.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BCS1L | NM_001079866.2 | c.232A>G | p.Ser78Gly | missense_variant | 2/8 | ENST00000359273.8 | NP_001073335.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BCS1L | ENST00000359273.8 | c.232A>G | p.Ser78Gly | missense_variant | 2/8 | 1 | NM_001079866.2 | ENSP00000352219 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000394 AC: 60AN: 152162Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000465 AC: 117AN: 251484Hom.: 0 AF XY: 0.000471 AC XY: 64AN XY: 135916
GnomAD4 exome AF: 0.000257 AC: 375AN: 1461888Hom.: 0 Cov.: 33 AF XY: 0.000257 AC XY: 187AN XY: 727242
GnomAD4 genome AF: 0.000394 AC: 60AN: 152280Hom.: 0 Cov.: 33 AF XY: 0.000631 AC XY: 47AN XY: 74454
ClinVar
Submissions by phenotype
GRACILE syndrome Pathogenic:7
Pathogenic, criteria provided, single submitter | clinical testing | Courtagen Diagnostics Laboratory, Courtagen Life Sciences | Sep 26, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU München | Sep 08, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2002 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Jan 19, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 14, 2016 | Variant summary: The BCS1L c.232A>G (p.Ser78Gly) variant involves the alteration of a conserved nucleotide. 4/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 48/122498 control chromosomes at a frequency of 0.0003918, which does not exceed the estimated maximal expected allele frequency of a pathogenic BCS1L variant (0.0004725). Homozygotes of this variant have been reported exclusively in Finnish patients with GRACILE syndrome. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 09, 2019 | NM_004328.4(BCS1L):c.232A>G(S78G) is classified as pathogenic in the context of BCS1L-related disorders. Sources cited for classification include the following: PMID 12215968 and 21274865. Classification of NM_004328.4(BCS1L):c.232A>G(S78G) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
not provided Pathogenic:4
Pathogenic, no assertion criteria provided | clinical testing | Laboratory of Molecular Genetics (Pr. Bezieau's lab), CHU de Nantes | Mar 08, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 29, 2023 | This sequence change replaces serine, which is neutral and polar, with glycine, which is neutral and non-polar, at codon 78 of the BCS1L protein (p.Ser78Gly). This variant is present in population databases (rs28937590, gnomAD 0.4%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individuals with clinical features of BCS1L-related conditions (PMID: 12215968, 12547234, 18386115, 19508421). It is commonly reported in individuals of Finnish ancestry (PMID: 12215968). ClinVar contains an entry for this variant (Variation ID: 6167). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BCS1L protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects BCS1L function (PMID: 12215968, 21274865). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 09, 2022 | Functional studies demonstrate that S78G is associated with decreased stability of the BCS1L protein (Visapaa et al., 2002); Transgenic mice with homozygosity for the S78G variant demonstrate decreased BCS1L expression and decreased Rieske iron-sulfur protein incorporation into complex III (Davoudi et al., 2014); This variant is associated with the following publications: (PMID: 21274865, 27997587, 29782205, 28424480, 30530468, 22829922, 18386115, 31980526, 12547234, 27809283, 32637629, 34662929, 24466228, 12215968) - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Oct 01, 2021 | - - |
Pili torti-deafness syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Dec 24, 2023 | - - |
Pili torti-deafness syndrome;C1864002:GRACILE syndrome;C3541471:Mitochondrial complex III deficiency nuclear type 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 12, 2022 | - - |
Mitochondrial complex III deficiency nuclear type 1 Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Jul 21, 2015 | - - |
BCS1L-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 19, 2024 | The BCS1L c.232A>G variant is predicted to result in the amino acid substitution p.Ser78Gly. This variant has been reported in the homozygous and compound heterozygous state in individuals with GRACILE syndrome (see, for example, Visapää et al. 2002. PubMed ID: 12215968 and Fellman et al. 2008. PubMed ID: 18386115). Transgenic mice homozygous for the p.Ser78Gly variant resemble the human syndrome with features including hepatopathy with progressive complex III deficiency and short lifespan (see for example Kotarsky et al. 2012. PubMed ID: 22829922). This variant is reported in 0.41% of alleles in individuals of European (Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/) and is interpreted as pathogenic by multiple laboratories in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/6167/). Based on the available evidence, this variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at